arrow
A

Anna Spreafico

Princess Margaret Cancer Centre
H指数:45
被引数:9,266

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types

通过RNA测序和多重免疫荧光成像对多种癌症类型的免疫特征分析

2026-09-090
OA
Metastatic patterns, outcomes, and prognostic factors in de novo metastatic head and neck cancer by tumor HPV status

转移模式、结局及按肿瘤HPV状态划分的原发转移性头颈癌的预后因素

2026-09-040
PRE
Validation of the ninth edition pathological and clinical TNM classifications for salivary gland carcinoma

第九版唾液腺癌病理与临床TNM分期的验证

2026-09-010
PRE
HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer

HPV血清学和循环病毒DNA在口咽癌中的检测、分型和疾病负担测量

2026-08-150
OAAI
CANLead: Canada as a Phase 1 Clinical Trial Leader — Opportunities, Initiatives, and Collaborative Innovation to Elevate National Competitiveness

CANLead:加拿大作为临床试验1期领导者——提升国家竞争力的机遇、倡议与合作创新

2026-05-220
OAAI
Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma

针对p16阳性头颈鳞状细胞癌经根治性(化疗)放疗后出现的异时性胸内转移,转移灶导向治疗的疗效影响

2026-05-130
PRE
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab

一种组织无关的全基因组甲基组富集检测的临床验证,用于监测帕博利珠单抗的治疗反应

2026-02-130
OAAI
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial

Binimetinib和encorafenib用于非-V600E BRAF突变晚期实体瘤的治疗:来自BEAVER II期试验的结果

2026-01-030
OAAI
Prevalence and Prognostic Value of Individual T4-defining Radiologic Features in HPV-Positive Oropharyngeal Carcinoma

HPV阳性口咽癌中单个T4定义影像学特征的发生率及预后价值

2025-12-230
PRE
Outcomes and characteristics of patients receiving pre-operative versus post-operative radiotherapy for sinonasal squamous cell carcinoma

接受术前与术后放疗的鼻腔及鼻窦鳞状细胞癌患者的结局与特征

2025-11-220
PRE
Risk factors and survival impact of severe radiation-related late toxicities in head and neck cancer–a cohort study

头颈癌中严重放射相关性晚期毒性的危险因素及生存影响——一项队列研究

2025-09-030
PREAI
T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab

细胞外DNA中的T细胞受体库作为接受帕博利珠单抗治疗患者肿瘤浸润细胞的替代标志物

2025-08-270
PREAI
The prognostic and predictive value of pre-treatment hematologic markers for oropharyngeal carcinoma stratified by HPV status and treated with definitive (chemo) radiation

根据HPV状态分层且接受根治性(化疗)放疗的口咽癌患者,其治疗前血液学标志物的预后和预测价值。

2025-06-010
OAAI
Factors associated with detection of oligometastatic recurrence and outcome following definitive (Chemo)radiotherapy for oropharyngeal carcinoma

与扁桃体癌确定性(化疗)放疗后寡转移复发检测及预后相关的因素

2025-06-010
OAAI